Special Issue "Viral Hepatitis and Hepatocellular Carcinoma"
Deadline for manuscript submissions: 31 August 2021.
Interests: Hepatocellular carcinoma； Epigenetics； Retrotransposons
As we know, ‘viral hepatitis’ is a broad term to describe liver damage due to hepatitis virus (A, B, C, D and E) infection. While hepatitis A and E viruses cause acute hepatitis; hepatitis B, C and D viruses can cause both acute and chronic infections. Chronic hepatitis can lead to complications such as cirrhosis, liver failure and liver cancer, especially hepatocellular carcinoma (HCC).
Hepatitis B and C virus (HBV and HCV) infections are leading cause of HCC worldwide. According to world health organisation (WHO) statistics, 500 million people are estimated to be infected with HBV or HCV worldwide. These viruses kill 1.5 million people a year; 1 in every 3 people has been exposed to either or both viruses and most infected people do not know about it due to dormant symptoms.
A safe and effective vaccine against HBV is now available and universal vaccination programs are being run aiming to eliminate HBV-related viral hepatitis as a public health threat by 2030. There is no vaccine for HCV however, a major advance in the liver field in last 5 years has been the introduction of direct acting antivirals (DAAs) targeting HCV infection. Although these agents are costly, it is now clear that the majority of patients can be cured of HCV infection thus reducing further complications and associated death rates. What is also increasingly clear, however, is that while this reduces HCC risk in infected individuals, the risk is not eliminated – in either the global population treated with antivirals, or in those with HCV receiving curative treatments for HCC. Why this risk persists is not presently known.
HCC is a stepwise process and involves a combination of genetic and epigenetic alterations. Hence, in this special issue I invite you to submit original articles, case reports or review articles to advance our existing knowledgebase regarding (i) viral hepatitis prevention or treatment, (ii) screening of chronic hepatitis patients to assess HCC development, (iii) molecular pathogenesis of viral hepatitis-related HCC development and (iv) novel treatment strategies for viral hepatitis-related HCC.
Dr. Ruchi Shukla
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Viral Hepatitis
- Liver Cancer
- Hepatocellular Carcinoma
- HCC Risk
- Cancer Prevention